References
- Todd M. Six laws of open source drug discovery. ChemMedChem. 2019;14(21):1804–1809.
- Årdal C, Røttingen J. Open source drug discovery in practice: a case study. PLoS Negl Trop Dis. 2012;6(9):e1827.
- Singh S. India takes an open source approach to drug discovery. Cell. 2008;133(2):201–203.
- DeLano W. The case for open-source software in drug discovery. Drug Discov Today. 2005;10(3):213–217.
- RXRX19: the first morphological imaging dataset on SARS-CoV-2 virus. Rxrx.ai, 2020. [Last accessed 2020 Aug 3]. Available from: https://www.rxrx.ai/rxrx19#Download
- Download CAS COVID-19 antiviral candidate compounds dataset. CAS. 2020. [cited 2020 Aug 3]. Available from: https://www.cas.org/covid-19-antiviral-compounds-dataset
- Bobrowski T, Alves V, Melo-Filho C, et al. Computational models identify several fda approved or experimental drugs as putative agents against SARS-CoV-2. ChemRxiv. 2020. DOI:https://doi.org/10.26434/chemrxiv.12153594
- Amin S, Jha T. Fight against novel coronavirus: A perspective of medicinal chemists. Eur J Med Chem. 2020;112559. DOI:https://doi.org/10.1016/j.ejmech.2020
- Sedova M, Jaroszewski L, Alisoltani A, et al. Coronavirus3D: 3D structural visualization of COVID-19 genomic divergence. Bioinformatics. 2020. DOI:https://doi.org/10.1093/bioinformatics/btaa550
- Woo H, Park S-J, Choi YK, et al. Modeling and simulation of a fully-glycosylated full-length SARS-CoV-2 spike protein in a viral membrane. bioRxiv Prepr Serv Biol. 2020; published online 2020 May 21. DOI:https://doi.org/10.1101/2020.05.20.103325
- Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336.
- Roivant Sciences. 2020. Roivant doses first patient in pivotal BREATHE clinical trial evaluating gimsilumab in COVID-19 patients for the prevention and treatment of acute respiratory distress syndrome [Internet]. [cited 2020 Aug 3]. Available from: https://roivant.com/roivant-doses-first-patient-in-pivotal-breathe-clinical-trial-evaluating-gimsilumab-in-covid-19-patients.html.
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2022483
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;1–13.
- Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11. DOI:https://doi.org/10.1038/s41467-020-16505-0